5 Min Read
(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock index futures were higher on Tuesday, a day after Federal Reserve Chair Janet Yellen expressed confidence in the health of the economy, but was less hawkish on raising interest rates in the near-term. Dow Jones industrial average futures were up 0.25 percent at 17,959, S&P 500 futures were up 0.19 percent at 2,112.25 and Nasdaq 100 futures were up 0.18 percent at 4,533.75.
** VALEANT PHARMACEUTICALS INTERNATIONAL INC, Monday close $28.85, -15.77 pct premarket
The Canadian drugmaker, under scrutiny for business and accounting practices, reported a lower-than-expected quarterly profit and cut its full-year earnings and revenue forecast.
** VERIZON COMMUNICATIONS INC, Monday close $50.71
** YAHOO INC, Monday close $37.07, -1.11 pct premarket
Verizon plans to submit a second-round bid of around $3 billion for Yahoo's core internet business, the Wall Street Journal reported, citing people familiar with the matter.
** ZIMMER BIOMET HOLDINGS INC, Monday close $121.54, -0.03 pct premarket
** LDR HOLDING CORP, Monday close $22.58, +62.49 pct premarket
Zimmer Biomet, a maker of orthopedic reconstructive products, said it would buy LDR in a deal valued at about $1 billion to expand its presence in the spine market.
** SAREPTA THERAPEUTICS INC, Monday close $16.05, +31.40 pct premarket
The drug developer said said the U.S. FDA has requested for additional data from an ongoing study for its muscle-wasting treatment as the agency decides whether to approve the drug or not.
** ALEXION PHARMACEUTICALS INC, Monday close $154.99, -9.23 pct premarket
The drugmaker said Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial.
** BIOGEN INC, Monday close $289.84, -9.43 pct premarket
Biogen said its experimental drug for treating multiple sclerosis, a nervous system disease affecting the brain and the spinal cord, did not meet the main goal of improving some symptoms in a mid-stage study.
** MERCK & CO, Monday close $57.17
** GILEAD SCIENCES INC, Monday close $87.6, -0.23 pct premarket
A U.S. judge on Monday found a pattern of misconduct by Merck including lying under oath and other unethical practices, freeing Gilead from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni.
** AXIALL CORP, Monday close $23.3, +7.30 pct premarket
Lotte Chemical Corp is bidding for U.S. chemicals maker Axiall and Hanwha Chemical Corp flagged a likely U.S. deal, as cash-flush South Korean chemicals firms target acquisitions in a hunt for new revenue streams.
** UNITED NATURAL FOODS INC, Monday close $38.83, +10.74 pct premarket
The organic and fresh food distributor forecast better-than-expected FY 2016 sales as a result of the acquisitions of Nor-Cal, Global Organic, Haddon House Food Products.
** GOLDMAN SACHS GROUP INC, Monday close $157.06
U.S. law enforcement officials are attempting to identify whether Goldman violated federal law after failing to flag a transaction in Malaysia, the Wall Street Journal reported, citing people it said were familiar with the investigation.
** INTERNATIONAL BUSINESS MACHINES CORP, Monday close $152.73, +0.05 pct premarket
IBM on Tuesday said it signed a $300 million, ten-year technology services agreement with Dubai's Emirates Airline .
** ALIBABA GROUP HOLDING LTD, Monday close $78.06, +0.27 pct premarket
Alibaba Executive Chairman Jack Ma "very much hopes" that the e-commerce firm's affiliate Ant Financial Services Group will list in Hong Kong, a spokeswoman for the online finance company quoted him as saying.
** TESLA MOTORS INC, Monday close $220.68, +1.05 pct premarket
Samsung SDI is making progress in talks with Tesla to supply batteries for the U.S. automaker's Model 3 electric car as well as its energy storage products, a source with direct knowledge of the matter told Reuters. (Compiled by Sruthi Shankar in Bengaluru; Editing by Maju Samuel)